A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAFV600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer

Josep Tabernero*, Eric Van Cutsem, Elena Garralda, David Tai, Filippo De Braud, Ravit Geva, Mark T.J. van Bussel, Katia Fiorella Dotti, Elena Elez, María J. De Miguel, Kevin Litwiler, Danielle Murphy, Michelle Edwards, Van Karlyle Morris

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Background: WNT974 is a small molecule inhibitor of Wnt signaling that specifically inhibits porcupine O-acyltransferase. This phase Ib dose-escalation study evaluated the maximum tolerated dose of WNT974 in combination with encorafenib and cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer with RNF43 mutations or RSPO fusions. Patients and Methods: Patients received once-daily encorafenib and weekly cetuximab, in addition to once-daily WNT974, in sequential dosing cohorts. In the first cohort, patients received 10-mg WNT974 (COMBO10), which was reduced in subsequent cohorts to 7.5-mg (COMBO7.5) or 5-mg (COMBO5) after dose-limiting toxicities (DLTs) were observed. Primary endpoints were incidence of DLTs and exposure to WNT974 and encorafenib. Secondary endpoints were anti-tumor activity and safety. Results: Twenty patients were enrolled (COMBO10, n = 4; COMBO7.5, n = 6; COMBO5, n = 10). DLTs were observed in 4 patients, including grade 3 hypercalcemia (COMBO10, n = 1; COMBO7.5, n = 1), grade 2 dysgeusia (COMBO10, n = 1), and lipase increased (COMBO10, n = 1). A high incidence of bone toxicities (n = 9) was reported, including rib fracture, spinal compression fracture, pathological fracture, foot fracture, hip fracture, and lumbar vertebral fracture. Serious adverse events were reported in 15 patients, most frequently bone fracture, hypercalcemia, and pleural effusion. The overall response rate was 10% and disease control rate 85%; most patients achieved stable disease as their best response. Conclusion: Concerns surrounding the safety and lack of preliminary evidence of improved anti-tumor activity of WNT974 + encorafenib + cetuximab, compared with previous encorafenib + cetuximab data, ultimately led to study discontinuation. Phase II was not initiated.

Original languageEnglish
Pages (from-to)230-238
Number of pages9
JournalOncologist
Volume28
Issue number3
DOIs
StatePublished - Mar 2023
Externally publishedYes

Keywords

  • WNT974
  • cetuximab
  • colorectal cancer
  • encorafenib
  • metastatic

Fingerprint

Dive into the research topics of 'A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAFV600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer'. Together they form a unique fingerprint.

Cite this